Episode 423: Understanding Infections and MS with Dr. Robert Fox
Release Date: 10/06/2025
RealTalk MS
Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi. In today's episode, you'll meet two participants from the TEAMS Study, a research study at the University of Illinois Chicago's UI Health, in conjunction with the University of Alabama Birmingham School of Public Health. TEAAMS is an acronym for Targeted Exercise for African-Americans with Multiple Sclerosis. And the study's research team analyzed the effects of a remotely delivered, racially tailored exercise training program among African Americans with MS...
info_outlineRealTalk MS
Being a caregiver for a loved one with MS isn't an easy job. And, while it may consume hours of your time, often, it's not your only job. Many caregivers are the only family members bringing in an income. So, in addition to their caregiving responsibilities, they may also be facing the responsibilities that go along with holding down a full-time job. This week, Diana Grazio joins me to discuss how she balances her roles and responsibilities as her partner's caregiver while holding down a full-time job. You have online opportunities tomorrow! Participate in the National MS...
info_outlineRealTalk MS
As researchers continue to learn about MS, it becomes clear that you can change the trajectory of your MS journey and improve your quality of life by making smart lifestyle choices. Quitting smoking and watching your alcohol and caffeine consumption are smart choices for everyone, and they can pay especially big dividends if you're living with MS. This week, Dr. Barbara Giesser discusses how smoking, consuming alcohol, and consuming caffeine can impact your MS. We're also sharing the details about the Black MS Experience Summit taking place on November 12th, and the Hispanic LatinX MS...
info_outlineRealTalk MS
When you're living with a chronic condition like MS, you want to be sure you're doing everything you can to preserve and promote good health. And, right now, you may be feeling confused about whether you should be getting vaccinated, and which vaccines are safe. It's understandable. Unfortunately, there's a lot of confusing information about vaccines and vaccinations floating around out there. This week, Dr. Lisa Doggett helps us get past all the unnecessary noise and hysteria and reviews the science-based vaccine recommendations for people living with MS. We're also talking about...
info_outlineRealTalk MS
Some disease-modifying therapies can change the trajectory of your MS journey. But gaining access to those medications isn't always as easy or straightforward as it should be. In the United States, insurance companies are most often the gatekeepers to prescription medications. This week, Cassandra Ashby shares a story that many of you may already be too familiar with, as she takes us through her family's long, hard, and confusing struggle to get the DMT that her newly-diagnosed daughter's neurologist prescribed. I We're also talking about the game-changing results of a study that...
info_outlineRealTalk MS
Just about a month ago, 9,600 researchers, clinicians, and representatives from patient advocacy organizations gathered in Barcelona for the European Committee on Treatment and Research in MS annual scientific congress, better known as ECTRIMS, the largest MS research conference in the world. Now that he's had an opportunity to review his notes and digest all of the science presented at ECTRIMS 2025, Dr. Bruce Bebo, the National MS Society's Executive Vice-President of Research, returns to the podcast to take us on a deep dive covering some of the most important research presented this year....
info_outlineRealTalk MS
Jan Janisch-Hanzlik lives with MS and is a participant in one of the clinical trials evaluating the safety and efficacy of CAR-T cell therapy for MS. Jan is the first person in the world to receive this one-and-done treatment, and this week, she's joining me to share her experience participating in the clinical trial. But you'll be especially interested in hearing how CAR-T cell therapy has impacted Jan's MS. Open enrollment for people with Medicare and for those who get their health insurance through the ACA healthcare.gov Marketplace begins this week, and we're talking about some of the...
info_outlineRealTalk MS
Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi. In today's episode, we're exploring the risks and rewards of participating in a clinical trial with Dr. Kathy Zackowski and Mimi Brown. Dr. Zackowski is the Associate Vice President of Research at the National MS Society, and she's going to offer an overview of the risks and benefits that you'll want to weigh in considering participating in a clinical trial. Mimi Brown lives with primary progressive MS, and Mimi is...
info_outlineRealTalk MS
From the earliest days of the COVID-19 pandemic, people living with MS have been justifiably concerned about how a COVID-19 infection might impact their MS. As the new "Stratus" strain of COVID-19 is currently surging in the United States, research is providing answers we didn't have five years ago. Dr. Robert Fox, the Managing Director of the NARCOMS Patient Registry, joins me to discuss how COVID-19 infections and other infections impact people with MS. As ECTRIMS, the world's largest MS research conference, approached, many attendees anticipated the FDA's decision on whether to approve...
info_outlineRealTalk MS
Last week, over 9600 MS researchers and clinicians gathered in Barcelona for the European Committee for Treatment and Research in Multiple Sclerosis annual scientific congress -- ECTRIMS 2025. Minutes after the conference adjourned, in what has become an annual tradition, Dr. Bruce Bebo, the Executive Vice President of Research at the National MS Society, joined me to share his initial thoughts on the science presented at the meeting. Then, Kristine Werner Ozug, a member of the RealTalk MS team who lives with MS, joined me to share her perspective on three non-stop days of...
info_outlineFrom the earliest days of the COVID-19 pandemic, people living with MS have been justifiably concerned about how a COVID-19 infection might impact their MS. As the new "Stratus" strain of COVID-19 is currently surging in the United States, research is providing answers we didn't have five years ago.

Dr. Robert Fox, the Managing Director of the NARCOMS Patient Registry, joins me to discuss how COVID-19 infections and other infections impact people with MS.
As ECTRIMS, the world's largest MS research conference, approached, many attendees anticipated the FDA's decision on whether to approve Tolebrutinib, the first in a new category of disease-modifying therapies. Instead, the FDA has requested additional time for its review. We'll fill you in on the FDA's new target action date, and explain why there's strong interest in this particular disease-modifying therapy.
We know there's a specific gene that increases the risk of someone developing MS. But have you ever wondered where that gene came from, or why it exists at all? At ECTRIMS, Professor Lars Fugger took us on a journey 5,000 years into the past to explain its origin. When I spoke with him, Professor Fugger also explained how events from ancient history are still affecting the risk of developing MS today. You won't want to miss this compelling conversation!
At ECTRIMS, I also caught up with Jason Tardio, the President, and Dr. Andreas Muehler, the Chief Medical Officer, from Immunic Therapeutics. We talked about how their investigative drug, vidofludimus calcium, could potentially benefit people with MS by combating inflammation, protecting the nervous system, and offering antiviral benefits.
We have a lot to talk about! Are you ready for RealTalk MS??!
This Week: Infections and MS, and more from ECTRIMS 2025! :22
FDA extends its review of Tolebrutinib 1:42
From ECTRIMS: Professor Lars Fugger discusses the origin of the gene that increases an individual's risk of developing MS 4:11
From ECTRIMS: Jason Tardio, President, and Dr. Andreas Muehler, Chief Medical Officer, at Immunic Therapeutics, discuss how vidofludimus calcium could potentially benefit people with MS 11:22
Dr. Robert Fox discusses what the research reveals about how COVID-19 infections and other infections impact people living with MS 16:34
Share this episode 32:00
Next week's episode 32:19
SHARE THIS EPISODE OF REALTALK MS
Just copy this link & paste it into your text or email: https://realtalkms.com/423
ADD YOUR VOICE TO THE CONVERSATION
I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!
Email: jon@realtalkms.com
Phone: (310) 526-2283
And don't forget to join us in the RealTalk MS Facebook group!
LINKS
If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com
PARTICIPATE: Take the Shaping Tomorrow Together Survey
https://s.alchemer.com/s3/Perspectives-on-MS
REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA
https://nmss.quorum.us/event/25463
SIGN UP: Become an MS Activist
https://nationalmssociety.org/advocacy
JOIN: The RealTalk MS Facebook Group
https://facebook.com/groups/realtalkms
DOWNLOAD: The RealTalk MS App for iOS Devices
https://itunes.apple.com/us/app/realtalk-ms/id1436917200
DOWNLOAD: The RealTalk MS App for Android Devices
https://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk
REVIEW: Give RealTalk MS a rating and review
http://www.realtalkms.com/review
Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.
RealTalk MS Episode 423
Guests: Professor Lars Fugger, Jason Tardio, Dr. Andreas Meuhler, and Dr. Robert Fox